Skip Navigation
Search Menu
Johns Hopkins Medicine International

In This Section      
Print This Page


The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Patients at the Hopkins Kimmel Cancer Center have access to some of the most innovative and advanced therapies in the world.

Because Kimmel Cancer Center research scientists and clinicians work closely together, new drugs and treatments developed in the laboratory are quickly transferred to the clinical setting, offering patients constantly improved therapeutic options.

The Kimmel Cancer Center is one of only 40 cancer centers in the United States designated by the National Cancer Institute as a Comprehensive Cancer Center, providing a wide spectrum of specialty programs for adults and children:

  • Blood and bone marrow cancers
  • Brain and spinal tumor program
  • Breast center
  • Colon cancer center
  • Gynecologic oncology program
  • Head and neck cancer center
  • Liver cancer center
  • Lung cancer program
  • Melanoma program
  • Pancreatic cancer center
  • Pediatric oncology
  • Prostate cancer and other genitourinary cancers

The Kimmel Cancer Center also offers complete family and patient services that include a Cancer Counseling Center, survivors and palliative care programs, and the Hackerman-Patz Patient and Family Pavilion for patients and their families traveling from out-of-town.

To learn more or to make an appointment, call +1-410-502-7683.

Discover Our Research

3D MRI Scans May Offer Better Way to Predict Survival After Targeted Chemo for Liver Tumors
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor’s blood supply – is working.  Read more about this new technology.

DNA Shed by Tumors Shows Promise for Noninvasive Screening
Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to noninvasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.  Learn more about this cancer breakthrough.

Investigational Drug May Increase Survival For Some Patients with Advanced Melanoma
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments. Read more about the findings.